Treatment with “suicide” genes stunted the growth of ovarian tumor in mice and may one day offer a way to treat the last stage of ovarian cancer in women, U.S. say scientists.
Currently, there is no effective treatment for advanced ovarian cancer that has been repeated after the primary surgery and chemotherapy, according to a press release from the American Association for Cancer Research.
In laboratory experiments on mice, researchers found that nanoparticles for delivery of diphtheria toxin-encoding DNA selectively expressed in ovarian cancer cells significantly decreased the growth of ovarian tumors. The results appear online in the journal Cancer Research.
“This report is certainly a cause for hope,” lead researcher Janet Sawicki, a professor at the Lankenau Institute for Medical Research, said in the press release. “We now have a new potential for the treatment of advanced ovarian cancer that has promised to target tumor cells and leaving healthy cells healthy.”
The new treatment, which could be tested on humans within 18 to 24 months, could be a breakthrough in the specific therapy for cancer, according to Dr. Edward Sausville, an associate editor of Cancer Research and associate director of research clinic in the Greenebaum Cancer Center, University of Maryland.
“In oncology, who have been studying ways to kill the tumor for a long time, but much of what he has clashed with the principle of real estate location, location, location. In other words, an effective therapy is not effective if you cannot reach the goal, “Sausville said the press release.
Related posts: